Multiparametric analyses in diagnostics and monitoring of autoimmune diseases: Current state and perspectives;Multiparameteranalytik in Diagnostik und Monitoring von Autoimmunerkrankungen: Stand und Perspektiven

LaboratoriumsMedizin

Volumn 35, Issue 6, 2011, Pages 375-382

  Conrad, Karsten ^a   Sack, Ulrich ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

auto immune disease; autoantibodies; autoimmune diagnostics; biomarker; multiparametric analysis

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER;

ARTICLE; AUTOIMMUNE DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MEDICAL CARE; PATIENT MONITORING; PERSONALIZED MEDICINE;

EID: 81055123718     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2011.051     Document Type: Article

References (54)

1. Feltcamp TE. The mystery of autoimmune diseases. In: Shoenfeld Y, editor. The decade of autoimmunity. Amsterdam: Elsevier Science B.V., 1999:1-5.
2. Galeazzi M, Gasbarrini G, Ghirardello A, Grandemange S, Hoffman HM, Manna R, et al. Autoinflammatory syndromes. Clin Exp Rheumatol 2006;24(Suppl 40):79-85.
3. Freeman HJ. Risk factors in familial forms of celiac disease. World J Gastroenterol 2010;16:1828-31.
4. Huber LC, Stanczyk J, Jüngel A, Gay S. Epigenetics in inflamma-tory rheumatic diseases. Arthritis Rheum 2007;56:3523-31.
5. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-43. (Pubitemid 27398022)
6. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010;34:168-77.
7. Prince EP. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 2005;10(Suppl 1):44-9.
8. Conrad K, Schößler W, Sack U. Verbesserung der serologischen Autoimmundiagnostik durch multiparametrische Autoantikörper-Analytik. In: Conrad K, Lehman W, Sack U, Schedler U, editors. Multiparameteranalytik- Methoden, Applikationen, Perspektiven. Berlin, Pabst Science Publishers, 2008:261-302.
9. Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr 2008;158:19-28. (Pubitemid 351268498)
10. Mierau R, Genth E. Sklerodermie-assoziierte Autoantikörper-klinische und diagnostische Relevanz. Z Rheumatol 2006;65:279-84.
11. Steen VD. Autoantibodies in Systemic Sclerosis. Semin Arthritis Rheum 2005;35:35-42. (Pubitemid 41111469)
12. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scandinavian J Immunol 2006;64:227-35. (Pubitemid 44215112)
13. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum 2010;62:1198-200.
14. Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009;68:234-7.
15. Kallenberg CG. Anti-C1q autoantibodies. Autoimmun Rev 1008;7:612-5.
16. Matsuki Y, Hidaka T, Matsumoto M, Fukushima K, Suzuki K. Systemic Lupus erythematosus demonstrating serum anti-GM1 antibody, with sudden onset of drop foot as the initial presentation. Internal Med 1999;38:729-32.
17. Sindern E, Stark E, Haas J, Steck AJ. Serum antibodies to GM1 and GM3-gangliosides in systemic lupus erythematosus with chronic inflammatory demyelinating polyradiculoneuropathy. Acta Neurol Scand 1991;83:399-402.
18. Kuwana M, Okazaki Y, Kajihara M, Kaburaki J, Miyazaki H, Kawakami Y, et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia withmegakaryocytic hypoplasia. Arthritis Rheum 2002;46:2148-59.
19. Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011;70:530-6.
20. Yasuoka H, Kuwana M. Autoantibody response against a novel testicular antigen protein highly expressed in testis (PHET) in SSc patients. Autoimmun Rev 2007;6:228-31. (Pubitemid 46274547)
21. Goëb V, Salle V, Duhaut P, Jouen F, Smail A, Ducroix JP, et al. Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome. Clin Exp Immunol. 2007;148: 281-7.
22. Locht H, Pelcka R, Manthorpe R. Clinical manifestations correlated to the prevalence of autoantibodies in a large (n = 321) cohort of patients with primary Sjögren's syndrome. A comparison of patients initially diagnosed according to the Copenhagen classification criteria with the American-European consensus criteria. Autoimmun Rev 4 2005;4:276-81. (Pubitemid 40884545)
23. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyo-pathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193-200.
24. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010;49:1726-33.
25. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. UK Adult Onset Myositis Immunogenetic Collaboration. Clinical and human leucocyte antigen class II haplo-type associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009;68:1621-5.
26. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 2009;48:607-12.
27. Hengstman GJ, Brouwer R, Vree Egberts WT, Seelig HP, Jongen PJ, van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69-75. (Pubitemid 34119026)
28. Hirakata M. Humoral aspects of polymyositis/dermatomyositis. Mod Rheumatol 2000;10:199-206.
29. Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006;73:646-54. (Pubitemid 44932242)
30. Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology 2010;49:2370-4.
31. Váncsa A, Gergely L, Ponyi A, Lakos G, Németh J, Szodoray P, et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010;77:125-30.
32. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann NY Acad Sci 2010;1184:134-53.
33. Häussermann A, Gillissen A, Seidel W. Das Anti-Jo-1-Syndrom-eine Sonderform der Myositis mit interstitieller Lungenerkrankung. Pneumologie 2010;64:496-503.
34. Feist E, Schneider ML, Brychcy M, Dörner T, Burmester GR, Hiepe F. A unique autoantibody pattern of positive anti-Jo-1, anti-U1RNP, and antiproteasome antibodies in autoimmune myositis as a diagnostic challenge. Ann Rheum Dis 2003;62:370-1. (Pubitemid 36363450)
35. Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011;10:150-4.
36. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statinassociated autoimmune myopathy. Arthritis Rheum 2011;63: 713-21.
37. Pluk H, van Engelen BG, Pruijn GJ. Anti-Mup44: the first inclusion body myositis-specific autoantibody. In: Conrad K, Chan EK, Fritzler MJ, Humbel RL, Meroni PL, Shoenfeld Y, editors. From prediction to prevention of autoimmune diseases. Pabst Science Publishers, Lengerich 2011:210.
38. Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 2009;58;1620-8.
39. Conrad K, Roggenbuck D, Reinhold D, Dörner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev 2010;9:431-5.
40. Voltz R. Marker paraneoplastischer neurologischer Erkrankungen. J Lab Med 2004;28:431-8. (Pubitemid 39487017)
41. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-79.
42. Shams'ili S, Grefkens J, deLeeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409-18. (Pubitemid 36644385)
43. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004;62:778-82. (Pubitemid 38298956)
44. Bernal F, Shams'ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003;60:230-4. (Pubitemid 36152014)
45. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003;53:580-7. (Pubitemid 36529431)
46. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001;50:339-48. (Pubitemid 32848736)
47. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiat 1996;61:270-8. (Pubitemid 26293722)
48. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal Nnuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001;50:301-11. (Pubitemid 32848732)
49. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-48. (Pubitemid 32510382)
50. Vernino S, Lennon VA. New purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000;47:297-305. (Pubitemid 30141838)
51. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A. Lang B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005;165:166-71. (Pubitemid 40984634)
52. De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993;178:2219-23. (Pubitemid 23344881)
53. Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000;342:21-7. (Pubitemid 30020656)
54. Rakocevic G, Raju R, Dalakas MC. Anti-Glutamic acid decarb-oxylase antibodies in the serum and cerebrospinal fluid of patients with stiff person syndrome. Arch Neurol 2004;61:902-4. (Pubitemid 38747330)